1IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2011[J]. Diabetes research and clinical practice, 2013.
2Centers for Disease Control and Prevention 2011 National diabetes fact sheet, 2011. http://www.cdc.gov/ diabetes/ pubs/pdf/ndfs_2011.pdf. Last accessed July 12, 2011.
1Gonz'alez-Quintero VH, Istwan NB, Rhea DJ, et al. The impact of glycemic control on neonatal outcome in singleton pregnancies complicated by gestational diabetes. Diabetes Care ,2{D7 ,30 :467-470.
2DCCT Research Group. Pregnancy outcomes in the Diabetes Control and complications Trial. Am J Obstet Gynecol 1996,174: 1343-1353.
3Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart:a randomized, double-blind cross over trial in type 1 diabetes. Diabetes Care ,1999 ,22 :801-805.
4Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart : a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med,2004,21:769-775.
5Pettitt DJ, Ospina P, Kolaczynski JW, et al . Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care, 2003,26: 183-186.
6Manthiesen ER, Kinsley B, Amiel SA, et al. Manternal glycemic control and hypoglycemia in type Ⅰ diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Dabetes Care, 2007,30:771-776.
7Pettitt D J, Ospina P, Howard C, et al. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus. Diabet Med, 2007,24:1129-1135.
8Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type Ⅰ diabetes pregnancy:a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol, 2008,198 :e1-186-e7.
1Yang W Y, Lu J M, Weng J P, et al. Prevalence of diabetes amongmen and women in China[J]. N Engl J Med, 2010, 362 1 ) : 1090- 1101.
2Del Prato S, Felton A M, Munro N, et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Recommendations from the global partnership for effective diabetes management[J], lnt J Clin Pract, 2005, 59 ( 2 ) : 1345-1355.
3Mudaliar S. Choice of early treatment regimen and impact on β -cell preservation in type 2 diabetes[J], lnt J Clin Pract, 2013, 67 (9) : 876-887,.
4Bretzel R G, Eckhard M, L,andgraf W, et al. Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond[J]. Diabetes Care, 2009, 32 ( Suppl 2 ) : 260-265.
5Gong Z, Jin Y, Zhang Y. Oral administration of a cholera toxin B subunit-insulin fusion protein produced in silkworm protectsagainst autoimmune diabetes [J]. J Biotechnol, 2005, 119 (1): 93-105.
6Meng Q, Wang W, Shi X, et al. Protection against autoi- mmune diabetes by silkworm-produced GFP-tagged CTB-insulin fusion protein [J]. Clin Dev hnmunol, 2011, 2011 (6): 1-14.
7Song HY, Abad MM, Mahoney CP, et al. Human insulin B chain but not A chain decreases the rate of diabetes in BB rats [J]. Diabetes Res Clin Prac, 1999, 46 (2): 109-114.
8Yuki Y, Hara-Yakoyama C, Guadiz AA, et ol. Production of recombinant cholera toxin B subunit-insulin B chain peptide hybrid protein by Brevibacillus choshinensis expression system as a nasal vaccine Bioeng, 2005, 92 against autoimmune diabetes [J]. Biotechnol (7): 803-809.
9Rosales-Mendoza S, Alpuche-Solis AG, Soria-Guerra RE, et a/. Expression of an Escherichla coli antigenic fusion protein comprising the heat labile toxin B subunit and the heat stable toxin, and its assembly as a functional oligomer in transpla- stomie tobacco plants [J]. Plant J, 2009, 57 (1) : 45-54.
10Nochi T, Takagi H, Yuki Y, et ol. Rice-based mucosal vac- cine as a global strategy for cold-chain-and needle-free vacci- nation [J]. Proc Natl Acad Sci USA, 2007, 104 (26): 10986- 10991.
